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Background: Patients with heart failure and preserved ejection fraction (HFPEF) represent at least half of the growing number of heart failure (HF) 
cases and most of these patients have risk factors for or extensive histories of coronary artery disease (CAD). The impact of CAD-related events on 
outcomes in patients with HFPEF is incompletely understood. This analysis investigates the effect of hospitalization for acute coronary syndrome 
(ACS) on subsequent death in patients with HFPEF.
Methods: The I-Preserve trial randomized 4128 patients age ≥ 60 y with NYHA II-IV HF and EF≥45% to irbesartan or placebo. Mean follow-up was 
49.5 mo for adjudicated clinical outcomes.
Results: Irbesartan treatment had no effect on the distribution of any of the clinical event outcomes. The etiology of HF was ischemic in 25% 
of the patients and many patients had a history of hypertension (89% of patients), diabetes mellitus (28%), anginal symptoms (40%), unstable 
angina (8%), myocardial infarction (24%) and PCI or CABG (14%). Despite this substrate of disease, myocardial infarction (114 patients; 2.8%) and 
unstable angina (39 patients; 0.9%) were relatively uncommon causes for first hospitalization. However, these intercurrent hospitalizations for ACS 
portended a very poor outcome, roughly doubling the hazard ratio for all-cause mortality [HR 1.7; 95% CI: 1.4-2.1; p<0.001], increasing the death 
rate from 4.9 deaths/ 100 patient years in those without an ACS hospitalization to 8.6 deaths/ 100 patient years in those with one or more ACS 
event. Not surprisingly, ACS hospitalization was associated with increased risk of death from myocardial infarction [HR 52.3; 95% CI: 25.2-108.6; 
p<0.001], but the risk of death from heart failure [HR 2.4; 95% CI: 1.4-3.8; p<0.001] was also increased after at least one ACS hospitalization. 
There was no significant effect on non-cardiovascular or sudden death.
Conclusions: Despite the high incidence of coronary artery disease and risk factors, acute coronary syndromes were relatively infrequent causes 
of first hospitalization in the I-Preserve trial. However, these events portend a markedly increased risk of death, especially due to heart failure and 
myocardial infarction.
